BioTelemetry, Inc. Reports Fourth Quarter 2017 Financial Results
Company Delivers Record Revenue and Adjusted EBITDA Exceeds Expectations
News
BioTelemetry, Inc. to Release Fourth Quarter 2017 Earnings Results on February 22, 2018
BioTelemetry, Inc. (NASDAQ:BEAT) will release its fourth quarter 2017 earnings on Thursday, February 22nd at 4:00 PM Eastern Time.
BioTelemetry, Inc. Enters Agreement to Provide Cardiac Monitoring for Apple’s Heart Study
BioTelemetry, Inc. (NASDAQ:BEAT), the leading mobile and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today a partnership with Apple (NASDAQ:AAPL) to provide cardiac monitoring services in conjunction with the Apple Heart Study.
Telcare, a Division of BioTelemetry, Inc., Announces Collaboration with Onduo in Diabetes Management Program
Telcare, the manufacturer of the world’s first FDA-cleared cellular-enabled blood glucose monitor, has entered into a strategic collaboration with Onduo, a joint venture created by Verily (an Alphabet company) and Sanofi. Under this partnership, Telcare will serve as the supplier of remote blood glucose systems and the resulting data for patients enrolled in Onduo’s groundbreaking diabetes management program.
BioTelemetry, Inc. Reports Third Quarter 2017 Financial Results
Company Posts Strong Growth with Integration Ahead of Schedule Reports Record Quarterly Revenue and Adjusted EBITDA
BioTelemetry, Inc. to Release Third Quarter 2017 Earnings Results on November 7, 2017
The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Tuesday, November 7, 2017.
BioTelemetry Research and AMRA Raise the Standard for Medical Imaging in NASH/NAFLD Clinical Trials
BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced that BioTelemetry Research, their leading global imaging and cardiac core lab, and AMRA, the international leader in body composition analysis, have formed an exclusive alliance for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) clinical trials.
Jim Cramer spoke with BioTelemetry CEO Joe Capper
Watch Joe Capper explain how BioTelemetry will benefit from tech giants chasing connected health business
BioTelemetry, Inc. Reports Second Quarter 2017 Financial Results
Reports Record Quarterly Revenue and EBITDA Raises Full Year 2017 Guidance
